E-mail

E-mail a Wiley Online Library Link

Miranda B. Kim, Ming-Hui Chen, Mário de Castro, Marian Loffredo, Philip W. Kantoff and Anthony V. D'Amico Defining the optimal approach to the patient with postradiation prostate-specific antigen recurrence using outcome data from a prospective randomized trial Cancer 119

Version of Record online: 24 JUN 2013 | DOI: 10.1002/cncr.28202

Despite unfavorable prostate-specific antigen kinetics at recurrence, unhealthy men may not benefit from androgen suppression therapy (AST); randomized controlled trials examining intermittent AST versus surveillance are needed. For healthy men with unfavorable prostate-specific antigen kinetics at recurrence, prostate cancer death rates are high despite AST, warranting randomized controlled trials to evaluate the impact on death when adding agents that prolong survival in men with metastatic castration-resistant prostate cancer to AST.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH